{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:21Z","timestamp":1792784961148,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Forschungskredit UZH Postdoc","award":["FK-19-046 to JS"],"award-info":[{"award-number":["FK-19-046 to JS"]}]},{"DOI":"10.13039\/501100008401","name":"Stiftung Professor Dr. Max Clo\u00ebtta","doi-asserted-by":"publisher","award":["To BM"],"award-info":[{"award-number":["To BM"]}],"id":[{"id":"10.13039\/501100008401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Systemic sclerosis (SSc) is a severe multi-organ disease with interstitial lung disease (ILD) being the major cause of death. While targeted therapies are emerging, biomarkers for sub-stratifying patients based on individual profiles are lacking. Herein, we investigated how levels of serum metabolites correlated with different stages of SSc and SSc-ILD. Serum samples of patients with SSc without ILD, stable and progressive SSc-ILD as well as of healthy controls (HC) were analysed using liquid targeted tandem mass spectrometry. The best discriminating profile consisted of 4 amino acids (AA) and 3 purine metabolites.\n                    <jats:sc>l<\/jats:sc>\n                    -tyrosine,\n                    <jats:sc>l<\/jats:sc>\n                    -tryptophan, and 1-methyl-adenosine distinguished HC from SSc patients.\n                    <jats:sc>l<\/jats:sc>\n                    -leucine,\n                    <jats:sc>l<\/jats:sc>\n                    -isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. In SSc-ILD, both,\n                    <jats:sc>l<\/jats:sc>\n                    -leucine and xanthosine negatively correlated with changes in FVC% predicted. Additionally, xanthosine was negatively correlated with changes in DLco% predicted and positively with the prognostic GAP index. Validation of\n                    <jats:sc>l<\/jats:sc>\n                    -leucine and\n                    <jats:sc>l<\/jats:sc>\n                    -isoleucine by an enzymatic assay confirmed both the sub-stratification of SSc-ILD patients and correlation with lung function and prognosis score. Serum metabolites may have potential as biomarkers for discriminating SSc patients based on the presence and severity of ILD. Confirmation in larger cohorts will be needed to appreciate their value for routine clinical care.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-78951-6","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T06:04:43Z","timestamp":1607925883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1038","volume":"10","author":[{"given":"C.","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Freiburghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schniering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"78951_CR1","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 76, 1897\u20131905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"78951_CR2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0486OC","author":"A-M Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold, A.-M. et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am. J. Respir. Crit. Care Med. https:\/\/doi.org\/10.1164\/rccm.201903-0486OC (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78951_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen, V. D. & Medsger, T. A. Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann. Rheum. Dis. 66, 940\u2013944. https:\/\/doi.org\/10.1136\/ard.2006.066068 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"78951_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248\u20131254. https:\/\/doi.org\/10.1164\/rccm.200706-877OC (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78951_CR5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh, N. S. et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol.. 69, 1670\u20131678. https:\/\/doi.org\/10.1002\/art.40130 (2017).","journal-title":"Arthritis Rheumatol.."},{"key":"78951_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","volume":"77","author":"W Wu","year":"2018","unstructured":"Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model. Ann. Rheum. Dis. 77, 1326\u20131332. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213201 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"78951_CR7","doi-asserted-by":"publisher","first-page":"e0149240","DOI":"10.1371\/journal.pone.0149240","volume":"11","author":"F Salaffi","year":"2016","unstructured":"Salaffi, F. et al. Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability. PLoS ONE 11, e0149240. https:\/\/doi.org\/10.1371\/journal.pone.0149240 (2016).","journal-title":"PLoS ONE"},{"key":"78951_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319894851","author":"A-M Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold, A.-M., Fretheim, H., Meier, C. & Maurer, B. Circulating biomarkers of systemic sclerosis\u2014interstitial lung disease. J. Scleroderma Relat. Disord. https:\/\/doi.org\/10.1177\/2397198319894851 (2020).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"78951_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1126\/science.aam7928","volume":"356","author":"SA Eming","year":"2017","unstructured":"Eming, S. A., Wynn, T. A. & Martin, P. Inflammation and metabolism in tissue repair and regeneration. Science 356, 1026\u20131030. https:\/\/doi.org\/10.1126\/science.aam7928 (2017).","journal-title":"Science"},{"key":"78951_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/mutage\/gev060","volume":"30","author":"TJ Athersuch","year":"2015","unstructured":"Athersuch, T. J. & Keun, H. C. Metabolic profiling in human exposome studies. Mutagenesis 30, 755\u2013762. https:\/\/doi.org\/10.1093\/mutage\/gev060 (2015).","journal-title":"Mutagenesis"},{"key":"78951_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","volume":"20","author":"MM Rinschen","year":"2019","unstructured":"Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 20, 353\u2013367. https:\/\/doi.org\/10.1038\/s41580-019-0108-4 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"78951_CR12","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1007\/978-1-4939-8570-8_17","volume":"263\u2013288","author":"NA Reisdorph","year":"1809","unstructured":"Reisdorph, N. A., Cruickshank-Quinn, C., Nkrumah-Elie, Y. & Reisdorph, R. Application of metabolomics in lung research. Methods Mol. Biol. (Clifton, N.J.) 263\u2013288, 2018. https:\/\/doi.org\/10.1007\/978-1-4939-8570-8_17 (1809).","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"78951_CR13","doi-asserted-by":"publisher","first-page":"e000183","DOI":"10.1136\/bmjresp-2017-000183","volume":"4","author":"YD Zhao","year":"2017","unstructured":"Zhao, Y. D. et al. Metabolic heterogeneity of idiopathic pulmonary fibrosis: A metabolomic study. BMJ Open Respir. Res. 4, e000183. https:\/\/doi.org\/10.1136\/bmjresp-2017-000183 (2017).","journal-title":"BMJ Open Respir. Res."},{"key":"78951_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/acs.jproteome.6b00156","volume":"15","author":"YP Kang","year":"2016","unstructured":"Kang, Y. P. et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J. Proteome Res. 15, 1717\u20131724. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00156 (2016).","journal-title":"J. Proteome Res."},{"key":"78951_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s42255-018-0013-8","volume":"1","author":"JD Rabinowitz","year":"2019","unstructured":"Rabinowitz, J. D. & Mutlu, G. M. A metabolic strategy to reverse fibrosis?. Nat. Metab. 1, 12\u201313. https:\/\/doi.org\/10.1038\/s42255-018-0013-8 (2019).","journal-title":"Nat. Metab."},{"key":"78951_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41591-018-0087-6","volume":"24","author":"S Rangarajan","year":"2018","unstructured":"Rangarajan, S. et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 24, 1121\u20131127. https:\/\/doi.org\/10.1038\/s41591-018-0087-6 (2018).","journal-title":"Nat. Med."},{"key":"78951_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s42255-018-0008-5","volume":"1","author":"X Zhao","year":"2019","unstructured":"Zhao, X. et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat. Metab. 1, 147\u2013157. https:\/\/doi.org\/10.1038\/s42255-018-0008-5 (2019).","journal-title":"Nat. Metab."},{"key":"78951_CR18","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie, N. et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am. J. Respir. Crit. Care Med. 192, 1462\u20131474. https:\/\/doi.org\/10.1164\/rccm.201504-0780OC (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78951_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/resp.13465","volume":"24","author":"MT Gaugg","year":"2019","unstructured":"Gaugg, M. T. et al. Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis. Respirology 24, 437\u2013444. https:\/\/doi.org\/10.1111\/resp.13465 (2019).","journal-title":"Respirology"},{"key":"78951_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12931-018-0714-2","volume":"19","author":"B Rindlisbacher","year":"2018","unstructured":"Rindlisbacher, B., Schmid, C., Geiser, T., Bovet, C. & Funke-Chambour, M. Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis\u2014A potential biomarker role for LysoPC. Respir. Res. 19, 7. https:\/\/doi.org\/10.1186\/s12931-018-0714-2 (2018).","journal-title":"Respir. Res."},{"key":"78951_CR21","doi-asserted-by":"publisher","first-page":"7626","DOI":"10.1038\/s41598-018-25992-7","volume":"8","author":"F Murgia","year":"2018","unstructured":"Murgia, F. et al. Metabolomic profile of systemic sclerosis patients. Sci. Rep. 8, 7626. https:\/\/doi.org\/10.1038\/s41598-018-25992-7 (2018).","journal-title":"Sci. Rep."},{"key":"78951_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpba.2018.09.021","volume":"162","author":"A Fernandez-Ochoa","year":"2019","unstructured":"Fernandez-Ochoa, A. et al. Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. J. Pharm. Biomed. Anal. 162, 82\u201390. https:\/\/doi.org\/10.1016\/j.jpba.2018.09.021 (2019).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"78951_CR23","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum."},{"key":"78951_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson, C. J. et al. Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Chest 145, 723\u2013728. https:\/\/doi.org\/10.1378\/chest.13-1474 (2014).","journal-title":"Chest"},{"key":"78951_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1164\/rccm.2111053","volume":"167","author":"AU Wells","year":"2003","unstructured":"Wells, A. U. et al. Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 167, 962\u2013969. https:\/\/doi.org\/10.1164\/rccm.2111053 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1955\u20131964","key":"78951_CR26","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. J. Ann. Rheum. Dis. 76(1955\u20131964), 2017. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468 (2017).","journal-title":"J. Ann. Rheum. Dis."},{"key":"78951_CR27","first-page":"269","volume":"13","author":"I Csipo","year":"1995","unstructured":"Csipo, I. et al. Decreased serum tryptophan and elevated neopterin levels in systemic sclerosis. Clin. Exp. Rheumatol. 13, 269\u2013270 (1995).","journal-title":"Clin. Exp. Rheumatol."},{"key":"78951_CR28","first-page":"530","volume":"126","author":"KC Meyer","year":"1995","unstructured":"Meyer, K. C. et al. Tryptophan metabolism in chronic inflammatory lung disease. J Lab Clin Med 126, 530\u2013540 (1995).","journal-title":"J Lab Clin Med"},{"key":"78951_CR29","doi-asserted-by":"publisher","first-page":"D608","DOI":"10.1093\/nar\/gkx1089","volume":"46","author":"DS Wishart","year":"2017","unstructured":"Wishart, D. S. et al. HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res. 46, D608\u2013D617. https:\/\/doi.org\/10.1093\/nar\/gkx1089 (2017).","journal-title":"Nucleic Acids Res."},{"key":"78951_CR30","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00018-018-2880-2","volume":"75","author":"DM Dolivo","year":"2018","unstructured":"Dolivo, D. M., Larson, S. A. & Dominko, T. Tryptophan metabolites kynurenine and serotonin regulate fibroblast activation and fibrosis. Cell Mol. Life Sci. 75, 3663\u20133681. https:\/\/doi.org\/10.1007\/s00018-018-2880-2 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"78951_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20101629","volume":"208","author":"C Dees","year":"2019","unstructured":"Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961\u2013972. https:\/\/doi.org\/10.1084\/jem.20101629 (2019).","journal-title":"J. Exp. Med."},{"key":"78951_CR32","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/ar2495","volume":"10","author":"L Beretta","year":"2008","unstructured":"Beretta, L. et al. A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res. Ther. 10, R103. https:\/\/doi.org\/10.1186\/ar2495 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"78951_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/1756-185X.13386","volume":"21","author":"S Chaturvedi","year":"2018","unstructured":"Chaturvedi, S. et al. 5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-beta1 induced non-canonical signaling pathways including STAT3: Implications for fibrotic diseases like scleroderma. Int. J. Rheum. Dis. 21, 2128\u20132138. https:\/\/doi.org\/10.1111\/1756-185X.13386 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"78951_CR34","doi-asserted-by":"crossref","unstructured":"Distler O. M. B., Vettori, S., Blumhardt, S., Frey, D., Distler, A., Beyer, C., Distler, J. H. The serotonin receptor 2 inhibitor terguride has beneficial effects on skin fibrosis: Results from a phase 2 proof of concept study. Ann. Rheum. Dis. 66 (2016).","DOI":"10.1136\/annrheumdis-2016-eular.5587"},{"issue":"Pt 6","key":"78951_CR35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/000456328702400608","volume":"24","author":"P Vreken","year":"1987","unstructured":"Vreken, P. & Tavenier, P. Urinary excretion of six modified nucleosides by patients with breast carcinoma. Ann. Clin. Biochem. 24(Pt 6), 598\u2013603. https:\/\/doi.org\/10.1177\/000456328702400608 (1987).","journal-title":"Ann. Clin. Biochem."},{"key":"78951_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/rcm.1290070605","volume":"7","author":"JI Langridge","year":"1993","unstructured":"Langridge, J. I. et al. Gas chromatography\/mass spectrometric analysis of urinary nucleosides in cancer patients; potential of modified nucleosides as tumour markers. Rapid Commun. Mass Spectrom. 7, 427\u2013434. https:\/\/doi.org\/10.1002\/rcm.1290070605 (1993).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"78951_CR37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/art.40554","volume":"70","author":"H Karmouty-Quintana","year":"2018","unstructured":"Karmouty-Quintana, H. et al. The antifibrotic effect of A2B adenosine receptor antagonism in a mouse model of dermal fibrosis. Arthritis Rheumatol. 70, 1673\u20131684. https:\/\/doi.org\/10.1002\/art.40554 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"78951_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.phrs.2013.08.004","volume":"76","author":"V Della Latta","year":"2013","unstructured":"Della Latta, V., Cabiati, M., Rocchiccioli, S., Del Ry, S. & Morales, M. A. The role of the adenosinergic system in lung fibrosis. Pharmacol. Res. 76, 182\u2013189. https:\/\/doi.org\/10.1016\/j.phrs.2013.08.004 (2013).","journal-title":"Pharmacol. Res."},{"key":"78951_CR39","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/art.21974","volume":"54","author":"ES Chan","year":"2006","unstructured":"Chan, E. S. et al. Adenosine A2A receptors in diffuse dermal fibrosis: Pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54, 2632\u20132642. https:\/\/doi.org\/10.1002\/art.21974 (2006).","journal-title":"Arthritis Rheum."},{"key":"78951_CR40","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1172\/JCI27303","volume":"116","author":"CX Sun","year":"2006","unstructured":"Sun, C. X. et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Investig. 116, 2173\u20132182. https:\/\/doi.org\/10.1172\/JCI27303 (2006).","journal-title":"J. Clin. Investig."},{"key":"78951_CR41","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1096\/fj.15-274845","volume":"30","author":"F Luo","year":"2016","unstructured":"Luo, F. et al. Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. FASEB J. 30, 874\u2013883. https:\/\/doi.org\/10.1096\/fj.15-274845 (2016).","journal-title":"FASEB J."},{"key":"78951_CR42","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1074\/jbc.M114.622571","volume":"290","author":"S Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay, S. et al. Reciprocal regulation of AMP-activated protein kinase and phospholipase D. J. Biol. Chem. 290, 6986\u20136993. https:\/\/doi.org\/10.1074\/jbc.M114.622571 (2015).","journal-title":"J. Biol. Chem."},{"key":"78951_CR43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/1440-1681.12622","volume":"43","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Exacerbated cardiac fibrosis induced by beta-adrenergic activation in old mice due to decreased AMPK activity. Clin. Exp. Pharmacol. Physiol. 43, 1029\u20131037. https:\/\/doi.org\/10.1111\/1440-1681.12622 (2016).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"78951_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lfs.2015.01.042","volume":"127","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Activation of AMPK by metformin inhibits TGF-beta-induced collagen production in mouse renal fibroblasts. Life Sci. 127, 59\u201365. https:\/\/doi.org\/10.1016\/j.lfs.2015.01.042 (2015).","journal-title":"Life Sci."},{"key":"78951_CR45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/s0300-9084(99)00221-7","volume":"81","author":"L Debelle","year":"1999","unstructured":"Debelle, L. & Alix, A. J. The structures of elastins and their function. Biochimie 81, 981\u2013994. https:\/\/doi.org\/10.1016\/s0300-9084(99)00221-7 (1999).","journal-title":"Biochimie"},{"key":"78951_CR46","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","volume":"3","author":"RG Jenkins","year":"2015","unstructured":"Jenkins, R. G. et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: An analysis from the prospective, multicentre PROFILE study. Lancet Respir. Med. 3, 462\u2013472. https:\/\/doi.org\/10.1016\/S2213-2600(15)00048-X (2015).","journal-title":"Lancet Respir. Med."},{"key":"78951_CR47","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1113\/jphysiol.2013.253203","volume":"591","author":"DJ Wilkinson","year":"2013","unstructured":"Wilkinson, D. J. et al. Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. J. Physiol. 591, 2911\u20132923. https:\/\/doi.org\/10.1113\/jphysiol.2013.253203 (2013).","journal-title":"J. Physiol."},{"key":"78951_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102373","author":"T Suto","year":"2019","unstructured":"Suto, T. & Karonitsch, T. The immunobiology of mTOR in autoimmunity. J. Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2019.102373 (2019).","journal-title":"J. Autoimmun."},{"key":"78951_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030778","author":"J Lawrence","year":"2018","unstructured":"Lawrence, J. & Nho, R. The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms19030778 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"78951_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","volume":"38","author":"O Distler","year":"2016","unstructured":"Distler, O. & Cozzio, A. Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy. Semin. Immunopathol. 38, 87\u201395. https:\/\/doi.org\/10.1007\/s00281-015-0551-z (2016).","journal-title":"Semin. Immunopathol."},{"key":"78951_CR51","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1021\/ac4016787","volume":"85","author":"S Chen","year":"2013","unstructured":"Chen, S. et al. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography\/triple quadrupole mass spectrometry. Anal. Chem. 85, 8326\u20138333. https:\/\/doi.org\/10.1021\/ac4016787 (2013).","journal-title":"Anal. Chem."},{"key":"78951_CR52","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076 (2019).","journal-title":"N. Engl. J. Med."},{"key":"78951_CR53","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7 (2016).","journal-title":"Lancet Respir. Med."},{"key":"78951_CR54","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier, F. M. et al. Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database. Ann. Rheum. Dis. 71, 1355\u20131360. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200742 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"78951_CR55","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/ard.2010.142489","volume":"70","author":"C Beyer","year":"2011","unstructured":"Beyer, C. et al. EUSTAR biobanking: Recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann. Rheum. Dis. 70, 1178\u20131182. https:\/\/doi.org\/10.1136\/ard.2010.142489 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"78951_CR56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11306-019-1585-3","volume":"15","author":"K Freiburghaus","year":"2019","unstructured":"Freiburghaus, K. et al. Metabolomics by UHPLC\u2013MS: Benefits provided by complementary use of Q-TOF and QQQ for pathway profiling. Metabolomics 15, 120. https:\/\/doi.org\/10.1007\/s11306-019-1585-3 (2019).","journal-title":"Metabolomics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78951-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78951-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T19:40:26Z","timestamp":1670355626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78951-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78951"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78951-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CM, KF, CB, JS, CN: none to declare. OD had speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Novartis, Roche, Menarini, Mepha, MSD, iQone, Pfizer, consultancy fees from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, iQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi, UCB, Amgen, Lilly, Target BioScience, Pfizer, project scoring fees from Abbvie, interview fees from Catenion, travel support from Pfizer, research grants from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd, Mitsubishi Tanabe, patent issued: mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). BM had grant\/research support from AbbVie, Protagen, Novartis, and congress support from Pfizer, Roche, Actelion, and MSD, speakers honorary from Novartis. In addition, B. Maurer has a patent mir-29 for the treatment of systemic sclerosis registered (US8247389, EP2331143). The real or perceived potential conflicts listed above are accurately stated. YA had consultancy relationships and\/or has received research funding from Actelion, Bayer, Boehringer Ingelheim, ChemomAb, Genentech\/Roche, Inventiva, Pfizer, Sanofi, Servier, in the area of potential treatments of scleroderma and its complications. AH received consulting fees and\/or research funding from Actelion, ARXX, Bayer, Boehringer Ingelheim, Medscape, MSD and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21912"}}